INTRODUCTION {#s1}
============

There were an estimated 76,960 new cases and 16,390 deaths from bladder cancer in the United States in 2016 \[[@R1]\]. Non-muscle invasive bladder cancer (NMIBC) continues to be a challenge to treat. Although low-risk tumors can be appropriately treated with resection alone, most other tumors require adjunct intravesical therapies to improve clinical outcomes. While various chemotherapies have played significant roles in mitigating recurrences, Bacillus Calmette--Guérin (BCG) immunotherapy remains the standard first line intravesical agent for intermediate and high-risk NMIBCs.

After binding to urothelial cells via a fibronectin-dependent pathway, BCG is taken in by urothelial and inflammatory cells, which triggers a substantial inflammatory and immunologic response \[[@R2]\]. A unique characteristic of BCG-induced inflammation is the prominent early recruitment of polymorphonuclear leukocytes (PMNs), which are found in disproportionately large numbers (75% of immune cells) in the urine after BCG instillation \[[@R3]\]. As is typical of an inflammatory response to bacterial infections, the cytokine profile of IL-2, IL-12, and IFN-γ seen after BCG exposure is that of a Th1 response \[[@R4], [@R5]\]. Because local inflammation is a key mediator of BCG response, efforts have been made to improve BCG efficacy by amplifying the Th1 response after BCG-stimulation with the co-administration of various associated cytokines such as IFN-α2β, IL-2, IL18, and IFN-γ \[[@R4], [@R6]\]. Although preclinical studies have shown some benefit, these results unfortunately have not translated into the clinical setting \[[@R5]\]. Studies have been conducted in other malignancies to identify inflammation-related biomarkers, focusing mostly on circulating inflammatory molecules as well \[[@R7]--[@R9]\]. However, this approach has yet to identify reliable predictive biomarkers, mainly due to variation in methodology and sample processing. On the other hand, inherited genetic variations could be more reliable alternatives due to their stability and reproducibility \[[@R7]\].

There have been no studies to assess the association between genetic variants within the inflammatory gene pathway and outcomes in NMIBC. Moreover, there are no studies addressing potential pathway SNPs associated with recurrence and progression in NMIBC patients who received BCG immunotherapy. Further identification of unfavorable genotypes in the inflammatory gene pathway may select patients most likely to benefit from upfront radical cystectomy as well as patients' likelihood of response to treatment. Thus, in the present study we utilize a pathway based approach to assess single nucleotide polymorphisms (SNPs) in the inflammatory gene pathway as predictors for recurrence and progression in NMIBC patients who underwent BCG immunotherapy and who underwent transurethral resection (TUR) alone.

RESULTS {#s2}
=======

Patient characteristics {#s2_1}
-----------------------

The characteristics of the discovery and validation study populations are shown in Table [1](#T1){ref-type="table"} and [Supplementary Table 1](#SD1){ref-type="supplementary-material"}. A total of 671 (349 in discovery, 322 in validation) were included in the analysis. There was no significant difference between patients in the discovery and validation phases who received BCG versus TUR only according to age, gender, smoking status, tumor size and recurrence. In both the discovery and validation phases, patients who underwent BCG were more likely to harbor carcinoma *in situ* (42.4% v 14.6%, *P*\<0.001) and have higher grade tumors (77.3% v 35.0%, *P*\<0.001). Patients in the discovery phase were more likely to progress than patients who underwent TUR only, however, this was not significantly different in the validation phase. Conversely, focality was not significantly different among BCG and TUR patients in the discovery phase. However, there were significantly more multifocal tumors among BCG than TUR only patients in the validation phase (28.7% v 15.9%, *P*=0.004), respectively. Since BCG was primarily administered to those with higher risk of recurrence, we compared different BCG treatments on risks of recurrence and progression. Compared to iBCG, mBCG treatment was significantly associated with reduced risks of recurrence and progression in both the discovery and validation phases (*P*\<0.01, data not shown).

###### Demographics of the study populations according to treatment type

  Variables^\*^                 Discovery     Validation                                              
  ----------------------------- ------------- ------------- ------------- ------------- ------------- -------------
  Age (y), Mean (SD) y          64.0 (10.2)   61.9 (12.7)   0.087         65.2 (10.9)   66.2 (10.7)   0.423
  Sex, No (%)                                                                                         
   Male                         170 (82.9)    111 (77.1)                  177 (84.7)    96 (85.0)     
   Female                       35 (17.1)     33 (22.9)     0.175         32 (15.3)     17 (15.0)     0.949
  Smoking status, No (%)                                                                              
   Never                        56 (27.3)     44 (30.6)                   59 (28.2)     34 (30.1)     
   Former                       107 (52.2)    67 (46.5)                   116 (55.5)    55 (48.7)     
   Current                      42 (20.5)     33 (22.9)     0.581         33 (15.8)     23 (20.4)     0.614
  Carcinoma *in situ*, No (%)                                                                         
   Yes                          87 (42.4)     21 (14.6)                   92 (44.0)     22 (19.5)     
   No                           111 (54.1)    118 (81.9)    **\<0.001**   89 (42.6)     71 (62.8)     **\<0.001**
  Tumor size, No (%)                                                                                  
   1-2cm                        27 (13.2)     19 (13.2)                   31 (14.8)     17 (15.0)     
   2-5cm                        34 (16.6)     31 (21.5)                   39 (18.7)     26 (23.0)     
   \>5cm                        16 (7.8)      4 (2.8)       0.183         14 (6.7)      6 (5.3)       0.791
  Stage                                                                                               
   Tis                          18 (8.8)      2 (1.4)                     70 (33.5)     68 (60.2)     
   Ta                           65 (31.9)     96 (67.1)                   13 (6.2)      3 (2.7)       
   T1                           121 (59.3)    45 (31.5)     **\<0.001**   121 (57.9)    35 (31.0)     **\<0.001**
  Grade                                                                                               
   G1                           4 (2.1)       8 (5.7)                     1 (0.5)       10 (8.8)      
   G2                           40 (20.6)     83 (59.3)                   30 (14.5)     56 (49.6)     
   G3                           150 (77.3)    49 (35.0)     **\<0.001**   168 (81.2)    42 (37.2)     **\<0.001**
  Focality                                                                                            
   1                            70 (34.1)     64 (44.4)                   47 (22.5)     45 (39.8)     
   2                            17 (8.3)      7 (4.9)                     24 (11.5)     13 (11.5)     
   Multiple                     54 (26.3)     25 (17.4)     0.075         60 (28.7)     18 (15.9)     **0.004**
  Treatment                                                                                           
   iBCG                         121 (59.0)                                105 (50.2)                  
   iBCG+mBCG                    84 (41.0)                                 104 (49.8)                  
  Recurrence                                                                                          
   No                           82 (40.0)     45 (31.3)                   126 (60.3)    65 (57.5)     
   Yes                          123 (60.0)    99 (68.8)     0.094         83 (39.7)     48 (42.5)     0.630
  Progression                                                                                         
   No                           148 (72.2)    125 (86.8)                  143 (68.4)    88 (77.9)     
   Yes                          57 (27.8)     19 (13.2)     **0.001**     66 (31.6)     25 (22.1)     0.720

SD: standard deviation; BCG: bacillus Calmette--Guerin immunotherapy; iBCG: induction BCG; mBCG: maintenance BCG; TUR: transurethral resection. Bold font denotes significant *P* values.

^\*^Numbers for each variable may not add to total due to missing data.

Associations between significantly opposing inflammatory genetic variants and recurrence {#s2_2}
----------------------------------------------------------------------------------------

For this study we genotyped 372 tagSNPs in 27 candidate genes of the inflammation pathway ([Supplementary Table 2](#SD2){ref-type="supplementary-material"}) and analyzed their association with NMIBC outcome. In the discovery phase, we identified 20 SNPs that were significantly associated with recurrence in patients treated with BCG but were not significant in the TUR only group, and the hazard ratios (HRs) were in opposite direction (Table [2](#T2){ref-type="table"}). Of these, rs3138056 in *NFKBIA* was the only SNP to have significant effect after correcting for multiple comparisons by Q value at a false discovery rate of ≤10% and conferred a 3.3-fold (95% CI, 1.83-5.8) increased risk of recurrence in patients who underwent BCG rather than TUR only treatment. To internally validate these results, we performed random bootstrap resampling of the significant SNPs for 100 iterations and listed the number of times that the *P* value was \<0.05. In BCG-treated patients, three SNPs had highly consistent results, with bootstrap *P* values \<0.05 for greater than 90% of samplings (rs3138056 in *NFKBIA*; rs951193 in *IL1R1* and rs4812997 in *CD40*) (data not shown).

###### Significantly opposing inflammatory gene variants associated with recurrence in NMIBC patients in the discovery cohort who received BCG and TUR only treatment

  SNP             Gene     MAF    MOI   TUR only     BCG                                                                               
  --------------- -------- ------ ----- ------------ ----------- ------------------ ------ ------------ ----------- ------------------ -----------------
  **rs3138056**   NFKBIA   0.32   REC   47\\40\\12   25\\13\\7   0.68 (0.36-1.28)   0.23   51\\57\\15   40\\39\\3   3.26 (1.83-5.8)    **6.20x10**^-5^
  rs3732131       IL1R1    0.07   DOM   90\\9\\0     36\\9\\0    0.78 (0.38-1.63)   0.52   106\\17\\0   78\\4\\0    2.45 (1.36-4.4)    2.89x10^-3^
  rs11607862      CD44     0.29   DOM   52\\38\\9    20\\23\\2   0.76 (0.5-1.16)    0.20   60\\47\\15   46\\29\\7   1.66 (1.13-2.44)   0.01
  rs8193          CD44     0.33   DOM   44\\44\\11   20\\21\\4   0.91 (0.6-1.39)    0.67   54\\53\\15   40\\33\\9   1.65 (1.11-2.46)   0.01
  rs228934        IL2RB    0.15   DOM   71\\24\\4    33\\10\\2   1.1 (0.69-1.75)    0.70   98\\22\\3    56\\23\\3   0.55 (0.34-0.88)   0.01
  rs4755391       CD44     0.23   DOM   49\\44\\6    28\\12\\5   1.19 (0.78-1.81)   0.42   74\\44\\3    43\\35\\3   0.63 (0.42-0.94)   0.02
  rs951193        IL1R1    0.05   DOM   88\\11\\0    38\\6\\1    0.75 (0.36-1.57)   0.45   110\\12\\1   78\\4\\0    2.03 (1.09-3.75)   0.02
  rs7956804^\#^   CD4      0.22   DOM   61\\36\\2    27\\18\\0   0.87 (0.56-1.34)   0.53   68\\51\\4    53\\23\\6   1.56 (1.05-2.32)   0.03
  rs5743700       TLR2     0.06   DOM   88\\11\\0    40\\4\\1    1.09 (0.54-2.22)   0.80   114\\7\\1    71\\11\\0   0.39 (0.17-0.91)   0.03
  rs2291473       ICAM1    0.15   DOM   69\\28\\2    35\\9\\1    1.34 (0.85-2.1)    0.20   91\\32\\0    53\\27\\2   0.62 (0.4-0.95)    0.03
  rs4812997       CD40     0.30   REC   50\\41\\8    28\\14\\3   0.81 (0.37-1.79)   0.60   55\\52\\16   37\\39\\6   1.86 (1.05-3.29)   0.03
  rs2241704       NFKBIB   0.23   DOM   48\\44\\7    27\\17\\1   1.3 (0.83-2.04)    0.25   84\\34\\5    45\\33\\4   0.63 (0.42-0.97)   0.03
  rs17009223      CD34     0.08   DOM   82\\16\\1    36\\8\\1    0.86 (0.49-1.49)   0.58   102\\20\\1   76\\6\\0    1.74 (1.04-2.91)   0.03
  rs2855537^\#^   CD4      0.22   DOM   62\\35\\2    27\\18\\0   0.91 (0.59-1.41)   0.68   68\\49\\4    51\\23\\6   1.53 (1.02-2.27)   0.04
  rs228935^\#^    IL2RB    0.16   DOM   69\\26\\4    32\\11\\2   1.04 (0.65-1.64)   0.88   95\\24\\4    55\\23\\4   0.62 (0.39-0.98)   0.04
  rs10911905      PTGS2    0.13   DOM   76\\22\\1    31\\13\\1   0.86 90.51-1.45)   0.57   88\\32\\3    67\\14\\1   1.57 (1.02-2.41)   0.04
  rs709592^\#^    CSF3     0.37   REC   40\\43\\16   20\\21\\4   1.36 (0.72-2.55)   0.34   49\\47\\25   33\\43\\6   1.64 (1.01-2.67)   0.04
  rs4795418^\#^   CSF3     0.37   REC   41\\42\\16   20\\21\\4   1.36 (0.72-2.55)   0.34   49\\47\\27   33\\44\\5   1.62 (1.01-2.59)   0.05
  rs4794823^\#^   CSF3     0.37   REC   41\\41\\16   20\\21\\4   1.36 (0.72-2.55)   0.34   49\\47\\27   33\\44\\5   1.62 (1.01-2.59)   0.05
  rs709591^\#^    CSF3     0.37   REC   40\\43\\16   20\\21\\4   1.36 (0.72-2.55)   0.34   49\\47\\26   33\\43\\6   1.62 (1.01-2.6)    0.05

^\*^Adjusted by age, gender, smoking status, carcinoma *in situ*, tumor size, grade, and treatment.

SNP that continued to be significant by Q value after correcting for multiple comparisons with a false discovery rate of ≤ 10% is in boldface. ^\#^SNPs with high linkage disequilibrium (LD; r^2^\>0.8): rs7956804 and rs2855537 in LD; rs709592 and rs4795418 in LD; rs709592 and rs4794823 in LD; rs709592 and rs709591 in LD; rs4795418 and rs4794823 in LD; rs4795418 and rs709591 in LD; rs4794823 and rs709591 in LD.

TUR: transurethral resection; BCG: Bacillus Calmette--Guérin immunotherapy; MAF, minor allele frequency; MOI: model of inheritance; Rec: recessive; dom: dominant; HR: hazard ratio; CI: confidence interval.

Among the 20 significantly opposing SNPs identified in the discovery phase, we selected 5 SNPs for further validation based on whole genome genotyping results from previously unpublished data. These variants showed consistent association in the new validation group (Table [3](#T3){ref-type="table"}). Among them, 2 SNPs (rs3732131 in *IL1R1* and rs228934 *in IL2RB*) remained significant in the meta-analysis, however, none reached significance during the validation phase.

###### Results for the significantly opposing inflammatory gene variants in NMIBC patients with BCG treatment associated with recurrence in the discovery, validation and meta-analysis

  *Recurrence*   Gene    MAF    MOI   Discovery          Validation   Meta-analysis                                 
  -------------- ------- ------ ----- ------------------ ------------ ------------------ ------- ------------------ -----------
  rs3732131      IL1R1   0.07   dom   2.45 (1.36-4.4)    **0.003**    1.04 (0.56-1.92)   0.903   1.63 (1.07-2.49)   **0.024**
  rs228934       IL2RB   0.15   dom   0.55 (0.34-0.88)   **0.01**     0.85 (0.55-1.30)   0.455   0.70 (0.51-0.96)   **0.028**
  rs4755391      CD44    0.23   dom   0.63 (0.42-0.94)   **0.02**     0.97 (0.64-1.47)   0.886   0.78 (0.58-1.04)   0.086
  rs951193       IL1R1   0.05   dom   2.03 (1.09-3.75)   **0.02**     1.06 (0.54-2.06)   0.872   1.51 (0.96-2.37)   0.077
  rs5743700      TLR2    0.06   dom   0.39 (0.17-0.91)   **0.03**     1.05 (0.57-1.95)   0.866   0.74 (0.45-1.22)   0.240

^\*^Adjusted by age, gender, smoking status, carcinoma *in situ*, tumor size, tumor grade, and treatment.

BCG: Bacillus Calmette--Guérin immunotherapy; MAF: minor allele frequency; MOI: model of inheritance; rec: recessive; dom: dominant; HR: hazard ratio; CI: confidence interval. Bold font denotes significant *P*-values.

Associations between significantly opposing inflammatory genetic variants and progression {#s2_3}
-----------------------------------------------------------------------------------------

In the discovery phase, we identified 15 significant opposing SNPs according to BCG therapy but not significant in the TUR only group (Table [4](#T4){ref-type="table"}). The most significant SNP was rs1800686 in the gene CD40 which conferred a 3.8-fold (95% CI, 1.55-9.37) increased risk of progression among BCG treated patients compared to those with TUR only treatment. To internally validate these results, we again performed random bootstrap resampling analysis. In BCG-treated patients, one SNP (rs7089861 in *IL2RA*) had highly consistent results, with bootstrap *P*-values \<0.05 for greater than 90% of samplings.

###### Significantly opposing inflammatory gene variants associated with progression in NMIBC patients in the discovery cohort who received BCG and TUR only treatment

  SNP              Gene    MAF    MOI   TUR only   BCG                                                                                 
  ---------------- ------- ------ ----- ---------- ------------ ------------------ ------ ------------ ------------ ------------------ --------
  rs1800686^\#^    CD40    0.24   REC   9\\10\\0   74\\46\\5    NA                 NA     24\\26\\7    83\\59\\6    3.81 (1.55-9.37    \<0.01
  rs2071081        CD4     0.21   REC   10\\9\\0   81\\39\\5    NA                 NA     33\\15\\9    93\\49\\6    3.19 (1.36-7.47)   0.01
  rs7089861        IL2RA   0.28   REC   13\\6\\0   66\\50\\9    NA                 NA     28\\21\\8    76\\60\\11   3.16 (1.38-7.22)   0.01
  rs1210225        CD34    0.21   DOM   12\\7\\0   74\\47\\4    0.92 (0.29-2.94)   0.89   34\\21\\2    96\\46\\6    2.11 (1.16-3.83)   0.01
  rs709592^\#^     CSF3    0.37   REC   10\\5\\4   50\\59\\16   0.91 (0.18-4.70)   0.91   21\\21\\15   61\\69\\16   2.24 (1.14-4.40)   0.02
  rs752118^\#^     CD40    0.26   REC   9\\10\\0   73\\47\\5    NA                 NA     24\\25\\8    83\\59\\6    2.88 (1.22-6.80)   0.02
  rs12309^\#^      CSF3    0.41   DOM   6\\11\\2   40\\64\\21   1.13 (0.35-3.67)   0.83   31\\13\\13   48\\74\\26   0.52 (0.29-0.93)   0.03
  rs2302777        CSF3    0.41   DOM   6\\11\\2   39\\65\\21   1.11 (0.34-3.60)   0.86   31\\13\\13   48\\75\\25   0.52 (0.29-0.93)   0.03
  rs2227315^\#^    CSF3    0.36   REC   10\\5\\4   50\\58\\15   0.92 (0.18-4.74)   0.92   21\\20\\14   60\\66\\16   2.15 (1.07-4.32)   0.03
  rs12722588^\#^   IL2RA   0.17   DOM   15\\4\\0   83\\40\\2    0.95 (0.29-3.07)   0.93   37\\18\\2    103\\43\\2   1.92 (1.04-3.57)   0.04
  rs2302776^\#^    CSF3    0.49   DOM   2\\13\\4   33\\58\\34   1.84 (0.39-8.64)   0.44   26\\18\\13   39\\69\\40   0.55 (0.31-0.98)   0.04
  rs709591^\#^     CSF3    0.37   REC   10\\5\\4   50\\59\\16   0.91 (0.18-4.70)   0.91   21\\21\\15   61\\69\\17   2.05 (1.05-4.00)   0.04
  rs7093069^\#^    IL2RA   0.17   DOM   15\\4\\0   83\\40\\2    0.95 (0.29-3.07)   0.93   37\\18\\2    103\\43\\2   1.92 (1.04-3.57)   0.04
  rs4794823^\#^    CSF3    0.37   REC   10\\5\\4   51\\57\\16   0.93 (0.18-4.80)   0.93   21\\21\\15   61\\70\\17   1.96 (1.00-3.84)   0.05
  rs4795418^\#^    CSF3    0.37   REC   10\\5\\4   51\\58\\16   0.91 (0.18-4.70)   0.91   21\\21\\15   61\\70\\17   1.96 (1.00-3.84)   0.05

\*Adjusted by age, gender, smoking status, carcinoma *in situ*, tumor size, tumor grade, and treatment.

^\#^SNPs with high linkage disequilibrium (LD; r^2^\>0.8): rs1800686 and rs752118 in LD; rs12309 and rs2302777 in LD; rs709592 and rs709591 in LD; rs709592 and rs4795418 in LD; rs709592 and rs2227315 in LD; rs709592 and rs4794823 in LD; rs709591 and rs4795418 in LD rs709591 and rs2227315 in LD; rs709591 and rs4794823 in LD; rs4795418 and rs2227315 in LD; rs4795418 and rs4794823 in LD; rs2227315 and rs4798423 in LD; rs12722588 and rs7093069 in LD.

TUR: transurethral resection; BCG: Bacillus Calmette--Guérin immunotherapy; MAF: minor allele frequency; MOI: model of inheritance; Rec: recessive; dom: dominant; HR: hazard ratio; CI: confidence interval.

Among the 15 SNPs identified in the discovery phase, 3 SNPs were selected for further genotyping in the validation phase (Table [5](#T5){ref-type="table"}). One SNP, rs7089861 in *IL2RA*, showed the same trend of effects between discovery and validation populations and reached statistical significance in the combined meta-analysis. In the discovery (HR =3.15, 95% Confidence Interval \[CI\]: 1.38-7.22, *P*\<0.01), validation (HR=3.84, 95% CI: 1.64-9.0, *P*=0.002) and meta-analysis (HR=3.47, 95% CI: 1.92-6.28, *P*\<0.001), rs7089861 was the only SNP significantly associated with risk of progression in the BCG treated group, respectively. Both rs1800686 and rs2071081 have probable association since HRs were of the same trend, but *P*-values were not significant during the validation phase. The meta-analysis was significant at *P*=0.002.

###### Results for the significantly opposing inflammatory gene variants in NMIBC patients with BCG treatment associated with progression in the discovery, validation and meta-analysis

  *Progression*   Gene    MAF    MOI   Discovery          Validation    Meta-analysis                                     
  --------------- ------- ------ ----- ------------------ ------------- ------------------ ----------- ------------------ -------------
  rs1800686       CD40    0.24   rec   3.81 (1.55-9.37)   **\<0.001**   1.91 (0.72-5.03)   0.191       2.77 (1.43-5.36)   **0.002**
  rs2071081       CD4     0.21   rec   3.19 (1.36-7.47)   **0.010**     1.24 (0.43-3.53)   0.693       2.19 (1.13-4.26)   **0.002**
  rs7089861       IL2RA   0.28   rec   3.15 (1.38-7.22)   **0.006**     3.84 (1.64-9.0)    **0.002**   3.47 (1.92-6.28)   **\<0.001**

^**\***^Adjusted by age, gender, smoking status, carcinoma *in situ*, tumor size, tumor grade, and treatment.

BCG: Bacillus Calmette--Guérin immunotherapy; MAF: minor allele frequency; MOI: model of inheritance; rec: recessive; dom: dominant; HR: hazard ratio; CI: confidence interval. Bold font denotes significant *P*-values.

Kaplan--Meier survival analysis also showed significant to borderline significant difference in progression free time by SNP rs7089861 genotype in the discovery and validation phases in patients who underwent BCG therapy (Figure [1](#F1){ref-type="fig"}). There was shorter median survival time (MST) with the presence of unfavorable rs7089861 genotype (homozygous minor alleles) compared to the low risk genotypes (homozygous and heterozygous wildtype alleles) (log rank *P*-values were 0.06 in the discovery phase and 0.04 in the validation phase).

![Kaplan--Meier estimates of progression-free survival in NMIBC patients\
Patients were grouped by the two risk groups as categorized by the presence or absence of the unfavorable rs7089861 genotype (homozygous minor alleles) in the inflammatory gene pathway. Number of events divided by total number (N) and progression-free median survival times (MST) in months were provided accordingly. **(A)** Kaplan--Meier estimates of progression-free survival in the BCG-treated group from the discovery cohort. **(B)** Kaplan--Meir estimates of progression-free survival in the BCG-treated group from the validation cohort.](oncotarget-08-88782-g001){#F1}

Functional characterization {#s2_4}
---------------------------

We performed functional characterization of the validated SNP rs7089861 and two SNPs (rs1800686 and rs2071081) showing probable association ([Supplementary Table 3](#SD3){ref-type="supplementary-material"}). There are no additional variants in high linkage disequilibrium (LD, r^2^\>0.8) with rs7089861 and rs2071081, while the region covering rs1800686 and its correlated variants (r^2^\>0.8) spans 27.5 kb. All three SNPs exhibited significant effect on promoter, enhancer, DNAse hypersensitivity and regulatory motif analysis in multiple tissues, while rs1800686 and rs2071081 also showed significant effect on protein binding analysis. Furthermore, we observed strong eQTL effect on regulatory gene function for rs1800686 on expression of *CD40* and *PLTP* and rs2071081 on expression of *CD4*, *GPR162*, and *LEPREL2* in multiple tissues ([Supplementary Table 4](#SD1){ref-type="supplementary-material"}).

DISCUSSION {#s3}
==========

We evaluated the association of variants within the inflammation pathway gene panel with recurrence and progression in patients who received BCG immunotherapy. Validation confirmed variant allele, rs7089861, was associated with risk of progression in the BCG treated group.

Of the 15 significant opposing SNPs for progression (i.e. significant for BCG therapy but not for TUR only group), we found one SNP, rs7089861, which was validated for progression in the BCG treated patients. In addition, a recent genome-wide association study showed that the association of rs7089861 with multiple sclerosis reached genome-wide significant level \[[@R10]\]. This SNP is in chromosome 10p15.1 and 6 kb from interleukin 2 (IL2) receptor subunit alpha (*IL2RA*) gene*.* Genomic region covering *IL2RA* is known to harbor the susceptibility loci for multiple sclerosis and type 1 diabetes \[[@R11]\]. Although we did not find apparent association of rs7089861 with *IL2RA* gene expression by eQTL analysis, rs7089861 showed significant functional potential through altered motifs on promoter and enhancer histone marks, DNAse hypersensitivity analysis, and the regulatory motif analysis (altered 6 motifs). *IL2RA* encodes IL-2Rα receptor protein which could form the high-affinity IL-2 receptor together with IL-2Rβ and IL-2Rγ. A soluble form of IL-2Rα could be detected in serum and altered expression level of soluble IL-2Rα have been shown to be associated with outcomes of various cancer types \[[@R12]\]. The IL-2/IL-2 receptor (IL-2R) pathway is critical for promoting the growth of T cell in response to antigen encounter. Further functional characterizations of IL-2Rα are needed to determine the effect of IL-2Rα on BCG response.

The most significant SNP in the discovery data was rs1800686 in the gene CD40. Although rs1800686 was not significant in the validation data, the hazard ratio in the validation was in the same direction, and the *P*-value for the meta-analysis was significant at 0.002. This SNP also showed eQTL effect with CD40 expression in skin, transformed fibroblasts, adipose, adrenal gland, adipocytes and blood samples. This gene is a member of the TNF-receptor superfamily. The encoded protein is a receptor on antigen-presenting cells of the immune system and is essential for mediating a broad variety of immune and inflammatory responses including T cell-dependent immunoglobulin class switching, memory B cell development, and germinal center formation \[[@R13]\]. AT-hook transcription factor AKNA is reported to coordinately regulate the expression of this receptor and its ligand, which may be important for homotypic cell interactions. Adaptor protein TNFR2 interacts with this receptor and serves as a mediator of the signal transduction \[[@R14], [@R15]\]. The interaction of this receptor and its ligand is found to be necessary for amyloid-beta-induced microglial activation, and thus is thought to be an early event in Alzheimer disease pathogenesis \[[@R16]\]. Mutations affecting this gene are the cause of autosomal recessive hyper-IgM immunodeficiency type 3 (HIGM3). Multiple alternatively spliced transcript variants of this gene encoding distinct isoforms have been reported \[[@R17]\]. The precise interplay of CD40 as it relates to NMIBC and BCG susceptibility remains to be elucidated.

Our findings must be interpreted in the context of the study design. We identified several polymorphisms associated with recurrence and progression among patients with NMIBC who received BCG immunotherapy. Since many of these inflammatory pathway SNPs are also important in immune responses, further research determining the exact interaction and potential for altered host immune response are needed to elucidate our findings. Although we considered adjustment for multiple testing, performed bootstrap sampling to internally validate these associations as well as replicated our findings in a separate group of patients, independent external studies are needed to confirm these results. Although there was no statistical difference between the discovery and validation sets for majority of the variables, age, carcinoma *in situ*, focality, and frequency of recurrence did differ between the two groups, which may lessen the likelihood of replication for some SNPs. Missing information for some clinical variables, such as tumor size and focality, may affect the final analysis in terms of adjustment for potential covariates. Additionally, we did not record specific number of maintenance courses, and we cannot comment on the SNP associations identified in the present study according to number of maintenance courses. Despite being adequately powered for overall analysis, our sample size may not be large enough to detect weaker associations and may be limited for some stratified analyses. Further validation of our findings and functional studies to identify biological basis for the observed associations are warranted.

In summary, we identified a set of SNPs within the inflammatory gene pathway associated with NMIBC outcome. One variant, rs7089861, was validated for progression and several SNPs with probable associations among patients who underwent BCG immunotherapy. Once replicated in independent studies, the identified loci may contribute to risk stratification protocol to identify patients most likely to benefit from BCG versus upfront radical cystectomy. Significant loci may point to potential therapeutic targets in the inflammation pathway to reduce the risk of NMIBC recurrence and progression.

MATERIALS AND METHODS {#s4}
=====================

Patient population and data collection {#s4_1}
--------------------------------------

Discovery population: Bladder cancer patients were recruited from the University of Texas MD Anderson Cancer Center and Baylor College of Medicine through a daily review of computerized appointment schedules as a part of an ongoing bladder cancer case--control study since 1995 \[[@R18]\]. To be eligible for this study, patients had to be histologically confirmed non-variant urothelial NMIBC and previously untreated with chemotherapy or radiation. In total, 349 NMIBC patients were selected for inclusion in the discovery. The study population has been described in detail previously \[[@R19]\]. There were no age, gender, ethnicity and cancer stage restrictions on recruitment.

Validation population: The validation patient population consisted of 322 histologically confirmed NMIBC cases similarly recruited from MD Anderson Cancer Center as the discovery group without any restrictions based on demographic or clinical criteria as part of an ongoing bladder cancer study. All patients were histologically confirmed NMIBC cases without prior treatment.

Patient demographic variables, tobacco and alcohol use history, family history of cancer and medical history were ascertained. Clinical information was abstracted from the medical records, including clinical stage, grade, pathological stage, histology, treatment, recurrence and progression. All patients provided written informed consent, and the study protocol has been approved by the institutional review board of MD Anderson Cancer Center and Baylor College of Medicine.

Genotyping {#s4_2}
----------

Genomic DNA was isolated from peripheral blood using the QIAamp DNA blood Maxi Kit (QIAGEN, Valencia, CA) according to the manufacturer's protocol as previously reported \[[@R18]\]. We combined literature exploration and database mining to select candidate genes in the inflammatory gene pathway \[[@R20]\]. A total of 372 SNPs in 27 selected target genes in the inflammation gene pathway were selected for genotyping and passed the quality control checking. The genotyping of the SNPs was done using Illumina's iSelect custom SNP array platform together with other cancer-related pathway SNPs according to the manufacturer's Infinium II assay protocol (Illumina, San Diego, CA). All of the patients' genotypes were called and exported using BeadStudio software (Illumina). The average call rate for the SNP array was 99.7%. Among the significant SNPs associated with NMIBC outcome, 8 SNPs (5 for recurrence and 3 for progression) were selected for further validation based on their consistent data with previously unpublished data. Validation genotyping of 8 candidate SNPs was performed using Taqman (Applied Biosystems). Functional characterization of SNPs were evaluated using HaploReg \[[@R21]\]. Expression quantitative trait loci (eQTL) analysis was performed using various annotation tools including SNIPA \[[@R22]\], GTEx \[[@R23]\], and HaploReg \[[@R21]\].

Statistical analysis {#s4_3}
--------------------

The primary endpoint events of this analysis were recurrence and progression, which was calculated from the date of diagnosis to the date of endpoint events, death or last follow-up, whichever came first. Tumor recurrence was defined as a newly detected bladder tumor following a negative follow-up cystoscopy. Tumor progression was defined as the transition from non-muscle invasive to invasive or metastatic disease. Patients who died or lost to follow-up before the endpoint events were censured. Comparisons of patient characteristics were analyzed using the Student *t*, Mann--Whitney, Chi-square or Fisher exact test, as appropriate. For smoking history patients who had never smoked or had smoked fewer than 100 cigarettes in a lifetime are considered never smokers while those who had smoked at least 100 cigarettes in a lifetime are considered ever smokers. The hazard ratio (HR) and the corresponding 95% confidence interval (CI) for the endpoints of interest were estimated by applying the multivariate Cox proportional hazards regression model while adjusting for patient age at diagnosis, gender, smoking status, stage, tumor grade and treatment.

Since several SNPs were tested in the analysis, the Q value, a measure of significance in terms of the false discovery rate, was used to adjust the significance level for multiple testing as previously reported \[[@R18], [@R24]\]. We calculated Q value by the Q value package implemented in the R software. In addition, we applied a bootstrap resampling method to internally validate the results. We generated 100 bootstrapped samples. Each time, a bootstrap sample was drawn from the original dataset and the *P* value was obtained for each SNP among the dominant, recessive and additive models. For each SNP dominant, recessive and additive models were analyzed, and only the best-fitting model was reported. Meta-analysis was performed to summarize the effects from discovery and validation populations. All statistical analyses were two sided. Kaplan--Meier curves were plotted for each genotype or unfavorable group, and log rank tests were applied to compare the difference between the event free survival time of each genotype or unfavorable group. Statistical analysis was done with Stata^®^, version 10 (College Station, TX, USA).
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==============================
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